[
    [
        {
            "time": "2019-04-29",
            "original_text": "上海医药关于全资子公司药品通过仿制药一致性评价的公告",
            "features": {
                "keywords": [
                    "上海医药",
                    "全资子公司",
                    "药品",
                    "仿制药",
                    "一致性评价"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "上海医药关于全资子公司药品通过仿制药一致性评价的公告",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-29",
            "original_text": "上海医药(02607)糖尿病药物“盐酸二甲双胍片”通过仿制药一致性评价",
            "features": {
                "keywords": [
                    "上海医药",
                    "糖尿病药物",
                    "盐酸二甲双胍片",
                    "仿制药",
                    "一致性评价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "上海医药(02607)糖尿病药物“盐酸二甲双胍片”通过仿制药一致性评价",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-04-29",
            "original_text": "上海医药:收入端显著提速，工商经营势头良好",
            "features": {
                "keywords": [
                    "上海医药",
                    "收入端",
                    "提速",
                    "工商经营",
                    "势头良好"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药:收入端显著提速，工商经营势头良好",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-29",
            "original_text": "【国泰君安国际策略速评】上海医药2019年一季度收入增长26%至460亿元，商业部分超预期增长，管理层对业务发展充满信心",
            "features": {
                "keywords": [
                    "国泰君安国际",
                    "上海医药",
                    "一季度",
                    "收入增长",
                    "商业部分",
                    "超预期增长",
                    "管理层信心"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国泰君安国际策略速评】上海医药2019年一季度收入增长26%至460亿元，商业部分超预期增长，管理层对业务发展充满信心",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-29",
            "original_text": "【东吴医药】医药周观点20190429:基金医药持仓比例11.3%，较2018年略有提升，建议积极关注有业绩保障的公司",
            "features": {
                "keywords": [
                    "东吴医药",
                    "基金",
                    "医药持仓",
                    "比例提升",
                    "业绩保障"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【东吴医药】医药周观点20190429:基金医药持仓比例11.3%，较2018年略有提升，建议积极关注有业绩保障的公司",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-29",
            "original_text": "恒指高开0.43%报29730点 比亚迪股份绩后高开4.7%",
            "features": {
                "keywords": [
                    "恒指",
                    "高开",
                    "比亚迪股份",
                    "绩后",
                    "涨幅"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "港股"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒指高开0.43%报29730点 比亚迪股份绩后高开4.7%",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-29",
            "original_text": "香港恒生指数开盘涨0.43% 长和等涨逾1%领涨蓝筹股",
            "features": {
                "keywords": [
                    "香港恒生指数",
                    "开盘涨",
                    "长和",
                    "蓝筹股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "港股"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "香港恒生指数开盘涨0.43% 长和等涨逾1%领涨蓝筹股",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 10,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-04-29",
            "original_text": "【港股异动 | 上海医药高开逾5 一季度净利润增长10.42%至11.26亿元】",
            "features": {
                "keywords": [
                    "港股异动",
                    "上海医药",
                    "高开",
                    "净利润增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【港股异动 | 上海医药高开逾5 一季度净利润增长10.42%至11.26亿元】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]